WNT3 decreases GCP proliferation by inhibiting SHH dependent gene transcription. by Sandrine L. Anne (489755)

“…<p>(<i>A</i>) WNT3 decreased proliferation of GCPs by 40.3± 5.0% of the control (Con) (n=3) as measured by [³H]-Thymidine incorporation assay. …”

Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. by Carlos González-Fernández (2794207)

Decreased β-catenin levels in the retinas of the diabetic and OIR KO mice. by Kelu Kevin Zhou (637715)

The expression of <i>Wnt1</i> gene was decreased in <i>Bmpr</i> double knockout mutants. by Lihua Qin (494786)

The TLR4 activator LPS decreases photoreceptor viability and reducesWnt-mediated protection from oxidative stress. by Hyun Yi (57741)

“…<p>(A) Muller glia-photoreceptor cultures were incubated for 24 hr in 0.4 mM H₂O₂ to induce oxidative stress, with and without recombinant Wnt3a (150 ng/ml) or the TLR4 activator LPS (5 and 50 µg/ml). …”

The frequency of co-expression of ALDH and CGA progressively decreases during colon tumorigenesis in FAP patients. by Tao Zhang (43681)

“…Fig 2F shows that in normal crypts, many cells staining for the colonic SC marker ALDH1 co-stained for chromogranin-A (CGA) and other NEC markers. In contrast, in <i>APC</i>-mutant tissues from familial-adenomatous-polyposis (FAP) patients, the proportion of ALDH+/CGA+ SCs progressively increased while ALDH+/CGA–PNCs, and ALDH+/CGA–NECs progressively decreased. …”

FHL2 silencing decreases osteosarcoma cell growth. by Julia Brun (286504)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Activation of Wnt/β-catenin signaling decreases mRNA expressions of <i>Scx</i>, <i>Mkx</i> and <i>Tnmd</i> in rat TDCs. by Yasuzumi Kishimoto (4282138)

“…<p>Relative expressions of <i>Axin2</i>, <i>Scx</i>, <i>Mkx</i>, and <i>Tnmd</i> in TDCs treated with 50 ng/ml Wnt3a with or without 5 μM IWR (an inhibitor of β-catenin) <b>(A)</b>, 0 to 4 μM BIO (an activator of β-catenin) <b>(B)</b>, or 0 to 20 μM IWR <b>(C)</b> for 72 hrs. …”

Reduced follicles, decreased ovulation and decreased fertilization of female Meox-2-cre/Separase S1121A mutant mice. by Juan Xu (225010)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…<p>(A) RFF is decreased by alterations in heart rate. …”

TEER of the Calu-3 cell monolayers measured at a 12-h interval. by Aizat Turdalieva (2512252)

“…Vertical lines indicate the time just before the medium change. The TEER of the cell monolayers decreased already during the first 12 h after the medium change.…”

Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

“…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”